Mega-company Johnson & Johnson is planning to break off its consumer products business from J&J’s pharmaceutical and medical device businesses, becoming two publicly traded companies.
Organon announced the women’s health company is acquiring Finland-based Forendo Pharma, which focuses on intracrinology or sex steroid physiology in women.
An alleged plan by Johnson & Johnson to spin off a company solely responsible for J&J’s talc-based products in order to mitigate lawsuit damages is still on the table following a ruling by a federal judge.
Calling herself a “change agent,” GlaxoSmithKline Chief Executive Officer Emma Walmsley outlined plans to transform the pharmaceuticals business of GSK following the expected spin-off of the company’s consumer health division during an investor conference.
FDA Issues CRL to Merck
Acquisitions, Agreements, Blockbusters, Business, Chemotherapy, Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency (EMA), FDA, Keytruda, Merck, Metastatic Urothelial Carcinoma (mUC), PD-1/PD-L1 inhibitors, Spin-offs, Therapeutics, Triple Negative Breast Cancer (TNBC)The U.S. Food and Drug Administration issued a Complete Response Letter (CRL) to Merck for the company’s supplemental Biologics License Application for Keytruda (pembrolizumab) in high-risk early-stage triple-negative breast cancer.
Amgen is partnering with Ann Arbor, Michigan-based EVOQ Therapeutics for a license and collaboration deal to discover and develop drugs for autoimmune disorders.
Sanofi is lining up to spin off the active pharmaceutical ingredients division that will include a listing as a public company, Reuters reported, citing unnamed sources.
With a busy week for biotech quarterly and annual reports, here is a look at some of the top stories.
Merck is spinning off products from the company’s Women’s Health, Legacy Brands and Biosimilars businesses.
Pfizer Inc. reported a higher-than-expected third-quarter 2019 profit on increased sales of the cancer drug Ibrance and a strong launch of the new heart medicine Vyndaqel.